Advertisement

Topics

BioNTech to Present at Cowen and Company’s 37th Annual Health Care Conference

19:00 EST 21 Feb 2017 | Globe Newswire

MAINZ, Germany, Feb. 22, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at Cowen and Company’s 37th Annual Health Care Conference that is being held in Boston, MA from March 6 - 8, 2017. The presentation is scheduled for Tuesday, March 7 at 10:00 AM Eastern Standard Time.

Mr. Marett will provide an overview of the Company´s strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations, a summary of its two most recent Nature publications related to its individualized mRNA cancer immunotherapeutics and the establishment of a GMP conform mRNA production facility at the Company´s headquarters in Germany.

About BioNTech AG
BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech´s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder. More information about BioNTech is available at www.biontech.com.

For meeting requests or further information, please contact:
BioNTech AG
Regina Jehle
Tel: +49 6131 9084 1273
Email: Regina.Jehle@biontech.de 

U.S. Media and Investor Inquiries:
ICR, Inc.
James Heins/Stephanie Carrington 
Tel. 203-682-8251
Tel. 646-277-1282
James.Heins@icrinc.com
Stephanie.Carrington@icrinc.com

International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
info@akampion.com
NEXT ARTICLE

More From BioPortfolio on "BioNTech to Present at Cowen and Company’s 37th Annual Health Care Conference"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...